Starting 2020, employees will be able to use health reimbursement arrangements (HRAs) to purchase individual coverage; New York has enacted legislation that ends nonmedical exemptions for school vaccination requirements; the FDA is being sued by Catalyst Pharmaceuticals over its approval of a similar orphan drug.
The Trump administration Thursday issued a final rule that will loosen restrictions on health reimbursement arrangements funded by employers with pretax dollars, which are currently used to pay for medical expenses. Under the rule, employees will be able to use special pretax health arrangements to buy individual health insurance, including plans that don’t comply with the Affordable Care Act, starting January 2020, according to The Wall Street Journal. The administration has said that the move will expand coverage to an estimated 800,000 previously uninsured people by 2029.
Governor Andrew Cuomo, D-New York, has signed legislation removing nonmedical exemptions from school vaccination requirements amid ongoing measles outbreaks in the state, reported CNN. The law, which will go into effect immediately, comes despite opposition from anti-vaccination activists and religious freedom advocates. New York has become the epicenter of the country’s ongoing measles outbreak, with more than 800 cases of measles over the last 9 months. California, Mississippi, West Virginia, and Maine do not allow nonmedical exemptions.
The FDA is being sued by Catalyst Pharmaceuticals, who is accusing the agency of “arbitrarily and capriciously” approving a similar medication made by Jacobus Pharmaceutical, according to STAT. Catalyst is alleging that the FDA did not adhere to the pharmaceutical company’s right to 7 years of exclusive marketing for its orphan drug for Lambert-Eaton myasthenic syndrome, or LEMS. Catalyst said the move undermines incentives for pharmaceutical companies to invest the money it takes to bring an orphan drug to market.
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
January 23rd 2024Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Interventions Needed to Increase DMT Uptake in Sickle Cell Disease
December 26th 2023A recent study found that uptake of disease-modifying therapies (DMTs) has been low among patients with sickle cell disease, suggesting that more interventions that consider individual patient characteristics are needed to improve adoption.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More